Amplia Therapeutics Limited (ATX:ASX)
Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3).